

NOTE: This table is to be used by Healthcare Professionals to assess clients with the following conditions who live or work in high-risk environments. This table does not address all Contraindications and Precautions.

Table of Contents:

- [SARS-CoV-2 \(COVID-19\) Infection Current or Previous](#)
- [Completion of an mRNA COVID-19 Vaccine Series](#)
- [Intervals between COVID-19 and other vaccines](#)
- [Treatment with COVID19 Monoclonal Antibodies or Convalescent Plasma](#)
- [Pregnancy or Planning Pregnancy](#)
- [Immunocompromised](#) (excluding cancer/oncology patients)
- [Immunocompromised- Cancer/Oncology Patients](#)
- [Autoimmune Conditions](#) (excluding Multiple Sclerosis patients)
- [Autoimmune Condition- Multiple Sclerosis Patients](#)
- [Tuberculin \(TB\) Skin Test or TB Blood Work \(IGRA\)](#)
- [Thrombosis and Thrombocytopenia](#)- for AstraZeneca COVID-19 vaccine only
 - **Contraindications included in this section**
- [Capillary Leak Syndrome](#) -for AstraZeneca COVID-19 vaccine only
 - **Contraindications included in this section**
- [Myocarditis and/or Pericarditis – for mRNA vaccines only](#)

Condition	Recommendations	Script
SARS-CoV-2 (COVID-19) Infection Current or Previous	NACI recommends that a complete series with a COVID-19 vaccine may be offered to individuals in the authorized age group without contraindications to the vaccine who have had previously PCR-confirmed SARS-CoV-2 infection (NACI July 22, 2021). NACI July 22, 2021 https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html?hq_e=eI&hq_m=2188311&hq_l=1&hq_v=91d220e044 .	<ul style="list-style-type: none"> • Individuals should wait to receive a vaccine until they no longer have acute symptoms of COVID-19 and are no longer infectious to others.
Completion of an mRNA COVID-19 Vaccine Series	<ul style="list-style-type: none"> • If easily available at the time of vaccination without delay or vaccine wastage, the same mRNA COVID-19 vaccine product should be offered for the subsequent dose in a vaccine series started with an mRNA COVID-19 vaccine. • If not easily available at the time of vaccination without delay or vaccine wastage or is unknown, another mRNA COVID-19 vaccine product recommended for use in that age group can be considered interchangeable and should be offered to complete the vaccine series. 	<ul style="list-style-type: none"> • Either mRNA COVID-19 vaccine can be used to complete a 2-dose vaccine series when the brand administered for the first dose is not available at the time for the second dose.
Intervals between COVID-19 and other vaccines	Intervals between the administration of COVID-19 vaccine and other vaccines previously required specific intervals. All Health Canada approved COVID-19 vaccines can be given concomitantly with other vaccines; no intervals are required before or after COVID-19 vaccine administration.	<ul style="list-style-type: none"> • COVID-19 vaccines may be given at the same time as other non-COVID-19 vaccines. No intervals

Condition	Recommendations	Script
<p>Treatment with COVID19 Monoclonal Antibodies or Convalescent Plasma</p>	<ul style="list-style-type: none"> If client received anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma for treatment of infection, delay vaccination with COVID-19 vaccine for at least 90 days. Delaying vaccination due to treatment is applicable to the first dose and second dose, depending on when treatment was received (e.g. if treatment is received after the first dose is administered, delay the second dose for at least 90 days). For persons receiving antibody therapies not specific to COVID-19 treatment (e.g., intravenous immunoglobulin, RhoGAM), they are recommended to receive and/or complete a full COVID-19 vaccine series either simultaneously with or at any interval before or after treatment. <p><u>NACI Recommendation:</u> NACI recommends that COVID-19 vaccines should not be given simultaneously with monoclonal antibodies or convalescent plasma.</p> <p>NACI July 22, 2021 https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html?hq_e=el&hq_m=2188311&hq_l=1&hq_v=91d220e044). Centre for Disease Control (US):</p> <p>People who previously received passive antibody therapy Currently, there are no data on the safety and efficacy of COVID-19 vaccines in people who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Based on the estimated half-life of such therapies and evidence suggesting that reinfection is uncommon in the 90 days after initial infection, vaccination should be deferred for at least 90 days. This is a precautionary measure until additional information becomes available, to avoid potential interference of the antibody therapy with vaccine-induced immune responses.</p> <p>For more information, see CDC clinical considerations: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html</p>	<p>are needed before or after COVID-19 vaccine administration.</p> <ul style="list-style-type: none"> Currently, there is insufficient evidence on the receipt of both a COVID-19 vaccine and anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma. Administering these products close together may result in less effectiveness of the COVID-19 vaccine and/ or the SARS-CoV-2 monoclonal antibodies. Based on your treatment the recommendation is to wait at least 90 days to receive the COVID-19 vaccine. (If recommendation in second column supports immunization) Do you have any additional questions or concerns about getting immunized with the COVID-19 vaccine?
<p>Pregnancy or Planning Pregnancy</p>	<p>Only mRNA COVID-19 vaccines should be offered during pregnancy unless there are contraindications. Viral vector COVID-19 vaccines should only be offered if there are allergies to mRNA vaccine ingredients or mRNA vaccine is not readily available.</p> <p><u>NOTE:</u> <u>Pregnancy is not a contraindication for any of the currently approved COVID-19 Vaccines, including AstraZeneca/COVISHIELD.</u></p> <p><u>NACI Recommendation</u></p>	<ul style="list-style-type: none"> Studies from around the world show COVID-19 vaccines are safe during pregnancy. Do you have any additional questions or concerns about getting immunized with the COVID-19 vaccine?

Condition	Recommendations	Script
	<p>NACI preferentially recommends that a complete vaccine series with an mRNA COVID19 vaccine should be offered to individuals in the authorized age group who are pregnant. If an mRNA vaccine is contraindicated, another authorized COVID-19 vaccine should be offered. Informed consent should include discussion about emerging evidence on the safety of mRNA COVID-19 vaccines in this population. (Strong NACI Recommendation)</p> <ul style="list-style-type: none"> An mRNA vaccine is preferred due to published safety data. Recently published preliminary analyses of 35,691 pregnant women in the United States who received an mRNA COVID-19 vaccine did not reveal any obvious safety signals. If VITT were to occur after receipt of a viral vector vaccine in a pregnant person, there might be complexity in the medical care. The US safety data suggests mRNA vaccine administration within 30 days of conception is safe. Those who are trying to become pregnant do not need to avoid pregnancy after vaccination with an mRNA vaccine. To date, no safety signals have been detected in Development and Reproductive Toxicity (DART) animal studies for Pfizer, Moderna, Janssen, and AstraZeneca vaccines. <p>NACI July 22, 2021 https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html?hq_e=el&hq_m=2188311&hq_l=1&hq_v=91d220e044).</p>	<ul style="list-style-type: none"> Do you consent to being immunized with the (Brand) of COVID-19 vaccine?
<p>Breastfeeding</p>	<p>Those who are breastfeeding should be offered COVID-19 immunization in the same manner as the general adult population.</p> <p><u>NACI Recommendation:</u> NACI recommends that a complete vaccine series with an mRNA COVID-19 vaccine should be offered to individuals in the authorized age group who are breastfeeding. If an mRNA vaccine is contraindicated, another authorized COVID-19 vaccine should be offered. Informed consent should include discussion about the emerging evidence on the safety of mRNA COVID-19 vaccines in this population. (Strong NACI Recommendation)</p> <p>NACI July 22, 2021 https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html?hq_e=el&hq_m=2188311&hq_l=1&hq_v=91d220e044).</p>	<ul style="list-style-type: none"> Studies from around the world show COVID-19 vaccines are safe while breastfeeding. Getting the COVID-19 vaccine is not a reason to stop breastfeeding. Do you have any additional questions or concerns about getting immunized with the COVID-19 vaccine? Do you consent to being immunized with the (Brand) of COVID-19 vaccine?
<p>Immunocompromised</p> <p>Also see sections below for Cancer/ Oncology patients</p> <p>And</p>	<p>It is preferred that clients on immunosuppressive therapy discuss the timing between their therapy and receiving the vaccine with their health care provider.</p> <p>(HSCT) Blood and Bone Marrow Stem Cell Transplant (autologous or allogeneic):</p> <ul style="list-style-type: none"> Patients MUST talk with their oncology team prior to vaccine administration. <ul style="list-style-type: none"> If feasible vaccine should be administered 2 weeks prior to starting conditioning regimen for their transplant. 	<ul style="list-style-type: none"> Studies from around the world show COVID-19 vaccines are safe for people with immune system conditions. The vaccine antibody response in immune comprised individuals may not be as strong as the immune response in individuals who are not immune suppressed.

Condition	Recommendations	Script
<p>Patients with Auto-Immune Disease</p>	<ul style="list-style-type: none"> ▪ Post-transplant - if transmission in the community is high, vaccination can be initiated 3 months after HSCT. If the transmission in the community is controlled, vaccination can wait until 6 months after HSCT. ▪ Postpone vaccination in severe, uncontrolled acute GVHD, Grade 3-4. <p>Medically stable SOLID ORGAN TRANSPLANT PATIENTS followed up by the Saskatchewan Transplant Program DO NOT NEED to consult their specialist prior to immunization with COVID-19 vaccines.</p> <p>However:</p> <ul style="list-style-type: none"> ○ If the client had a recent transplant (less than month ago) or was recently (less than 1 month ago) treated for rejection or if the immunizer is unsure of the client’s eligibility, please ask the client to contact the Saskatchewan Transplant Program to determine if and when they should receive the vaccine. <ul style="list-style-type: none"> • It is preferred that all other clients with immune suppression discuss the vaccine with their healthcare provider prior to presenting. However: <ul style="list-style-type: none"> ○ If they have not discussed vaccination with their healthcare provider AND their condition is UNSTABLE consult with the area MHO. ○ If they have not discussed vaccination with their healthcare provider AND their condition is stable proceed as below. <p><u>NACI Recommendation</u> NACI preferentially recommends that a complete COVID-19 vaccine series with an mRNA COVID-19 vaccine should be offered to individuals in the authorized age group who are immunosuppressed due to disease or treatment. If an mRNA vaccine is contraindicated, another authorized COVID-19 vaccine should be offered. Informed consent should include discussion about the possibility that individuals who are immunosuppressed may have a diminished immune response to any of the authorized COVID-19 vaccines. (Strong NACI Recommendation)</p> <p>NACI July 22, 2021 https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html?hq_e=el&hq_m=2188311&hq_l=1&hq_v=91d220e044.</p>	<p>Immunized individuals still need to take precautions against COVID–19 disease.</p> <ul style="list-style-type: none"> • Do you have any additional questions or concerns about getting immunized with the COVID-19 vaccine? • (If the treatment plan in second column supports immunization) Do you consent to being immunized with the (Brand) of COVID-19 vaccine?
<p>Immuno-compromised</p> <p>Oncology Patients</p>	<p>Cancer survivors should be vaccinated against COVID-19 if there are no contraindications to receiving vaccine. Vaccinate as any other client who does not have a precaution or contraindication.</p> <p>(HSCT) Blood and Bone Marrow Stem Cell Transplant (autologous or allogeneic):</p> <ul style="list-style-type: none"> ○ Patients MUST talk with their oncology team prior to vaccine administration. <ul style="list-style-type: none"> ▪ If feasible vaccine should be administered 2 weeks prior to starting conditioning regimen for their transplant. 	<ul style="list-style-type: none"> • Studies from around the world show COVID-19 vaccines are safe for people with immune system conditions. • The vaccine antibody response in immune comprised individuals may not be as strong as the immune response in individuals who are not immune suppressed.

Condition	Recommendations	Script
	<ul style="list-style-type: none"> ▪ Post-transplant - if transmission in the community is high, vaccination can be initiated 3 months after HSCT. If the transmission in the community is controlled, vaccination can wait until 6 months after HSCT. ▪ Postpone vaccination in severe, uncontrolled acute GVHD, Grade 3-4. <p>• It is preferred that all other clients with cancer discuss the vaccine with their healthcare provider prior to presenting. However:</p> <ul style="list-style-type: none"> ○ If they have not discussed vaccination with their healthcare provider AND their condition is UNSTABLE, consult with the area MHO. ○ If they have not discussed vaccination with their healthcare provider AND their condition is STABLE proceed as below. <p>The following guidelines on the timing of COVID-19 vaccine in terms of cancer treatment has been adapted from the information from inactivated influenza and other vaccines in immunocompromised patients.</p> <p>If client’s therapy is:</p> <ul style="list-style-type: none"> • Targeted Hormonal and single agent immune therapy treatments: Vaccine can be administered at any time during treatment. • Radiation therapy: Vaccine can be administered at any time during radiation therapy. • Cytotoxic chemotherapy: <ul style="list-style-type: none"> ○ New treatment starts: <ul style="list-style-type: none"> ▪ If possible, vaccination should be completed at least two weeks prior to starting systemic therapy or immunosuppressive therapy. If both of the doses cannot be given prior to starting treatment, at least the first dose of vaccine should be given two weeks before starting treatment. The second dose should be administered 4-5 days prior to the next cycle. ○ Patients already on chemotherapy treatment: <ul style="list-style-type: none"> ▪ Ideally a vaccine dose would be administered 4- 5 days prior to a dose of cytotoxic chemotherapy so that vaccine side effects and chemotherapy side effects don’t overlap. • B-Cell directed therapy ((Anti CD 20 (rituximab, obinotuzimab), CD 19 – (blinatumomab), CD 22 antibodies (inotuzumab) and BTK inhibitors (ibrutinib)): <ul style="list-style-type: none"> ○ If therapy is of short duration (limited number of cycles), Vaccination should be postponed until 1-3 months after B- cell directed treatment due to decreased ability to develop immunity to COVID-19 by vaccination. 	<p>Immunized individuals still need to take precautions against COVID–19 disease.</p> <ul style="list-style-type: none"> • Based on your therapy the recommendation is as follows: refer to treatments in second column. • Do you have any additional questions or concerns about getting immunized with the COVID-19 vaccine? • (If the treatment plan in second column supports immunization) Do you consent to being immunized with the (Brand) of COVID-19 vaccine?

Condition	Recommendations	Script
	<ul style="list-style-type: none"> ○ If therapy is part of a maintenance treatment, Vaccination should be given 4 weeks after the last dose of therapy. ○ Patients on BTK inhibitors (ibrutinib) can receive vaccination at any time. ● T-Cell directed therapy (Calcineurin inhibitors (e.g. oral and injection: cyclosporine and tacrolimus) (e.g. topical: pimecrolimus, tacrolimus), ATG (e.g. antithymocyte globulin – rabbit and equine) or Alemtuzumab) <ul style="list-style-type: none"> ○ Vaccination should be postponed until 3 months after of T- cell directed treatment due to decreased ability to develop immunity to COVID-19 by vaccination. <p><u>NACI Recommendation</u> NACI preferentially recommends that a complete COVID-19 vaccine series with an mRNA COVID-19 vaccine should be offered to individuals in the authorized age group who are immunosuppressed due to disease or treatment. If an mRNA vaccine is contraindicated, another authorized COVID-19 vaccine should be offered. Informed consent should include discussion about the possibility that individuals who are immunosuppressed may have a diminished immune response to any of the authorized COVID-19 vaccines. (Strong NACI Recommendation)</p> <p>NACI July 22, 2021 https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html?hq_e=el&hq_m=2188311&hq_l=1&hq_v=91d220e044.</p>	
<p>Autoimmune conditions</p> <p>See MS section below</p>	<p>For any autoimmune condition that involves the neurological system, it is preferred the client discuss vaccination with their primary physician / specialist before immunization is provided. If the client has not discussed vaccination with their primary physician or specialist, immunization can proceed with their informed consent.</p> <p>Clients receiving ongoing treatment with Rituximab should delay vaccination until a minimum of 4 weeks after last dose of Rituximab, unless directed differently by their health care provider/prescriber.</p> <ul style="list-style-type: none"> ● See table below for a list of common autoimmune conditions. ● It is preferred that clients with immune suppression discuss the vaccine with their healthcare provider prior to presenting. However: <ul style="list-style-type: none"> ○ If they have not discussed vaccination with their healthcare provider AND their condition is UNSTABLE consult with the area MHO. ○ If they have not discussed vaccination with their healthcare provider AND their condition is STABLE proceed as below. <p><u>NACI Recommendation:</u> NACI preferentially recommends that a complete vaccine series with an mRNA COVID19 vaccine should be offered to individuals in the authorized age group with an autoimmune condition. If an mRNA</p>	<ul style="list-style-type: none"> ● Studies from around the world show COVID-19 vaccines are safe for people with an autoimmune disease. ● The vaccine antibody response in individuals with autoimmune conditions may not be as strong as the immune response in individuals who do not have an autoimmune condition. The immune response may vary according to condition severity and current medical treatment. Immunized individuals still need to take precautions against COVID–19 disease. ● Do you have any additional questions or concerns about

Condition	Recommendations	Script																
	<p>vaccine is contraindicated, another authorized COVID-19 vaccine should be offered. Informed consent should include discussion about the emerging evidence on the safety of mRNA COVID-19 vaccines in these populations. (Strong NACI Recommendation)</p> <p>NACI July 22, 2021 https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html?hq_e=el&hq_m=2188311&hq_l=1&hq_v=91d220e044.</p>	<p>getting immunized with the COVID-19 vaccine?</p> <ul style="list-style-type: none"> • (If the treatment plan in second column supports immunization) Do you consent to being immunized with the (Brand) of COVID-19 vaccine? 																
<p>Autoimmune disorders</p> <p>MULTIPLE SCLEROSIS</p>	<ul style="list-style-type: none"> • It is preferred that clients with Multiple Sclerosis (MS) discuss the vaccine with their healthcare provider prior to presenting. However: <ul style="list-style-type: none"> ○ If they have not discussed vaccination with their healthcare provider AND their condition is UNSTABLE consult with the area MHO. ○ If they have not discussed vaccination with their healthcare provider AND their condition is stable proceed as below, taking into consideration the timing of vaccines based on Disease Modifying Therapies (See Table below). <p>For MULTIPLE SCLEROSIS (MS) patients the following recommendations should be followed:</p> <table border="1" data-bbox="417 756 1560 1446"> <thead> <tr> <th data-bbox="417 756 741 824">Medication(s)</th> <th data-bbox="741 756 1012 824">Effect on vaccination</th> <th data-bbox="1012 756 1291 824">Delay of vaccination after treatment*</th> <th data-bbox="1291 756 1560 824">Delay of treatment after vaccination**</th> </tr> </thead> <tbody> <tr> <td data-bbox="417 824 741 1151"> Glatiramer acetate (any type) Interferon-beta (any type) Teriflunomide Dimethyl fumarate (or any type of fumaric acid ester) Natalizumab </td> <td data-bbox="741 824 1012 1151"> Little to no effect </td> <td data-bbox="1012 824 1291 1151"> None required </td> <td data-bbox="1291 824 1560 1151"> None required </td> </tr> <tr> <td data-bbox="417 1151 741 1317"> Fingolimod Ozanimod Siponimod </td> <td data-bbox="741 1151 1012 1317"> May have a modest decrease in vaccine effectiveness </td> <td data-bbox="1012 1151 1291 1317"> None required </td> <td data-bbox="1291 1151 1560 1317"> 4 weeks for treatment initiation; no delay for treatment continuation </td> </tr> <tr> <td data-bbox="417 1317 741 1446"> Ocrelizumab Rituximab </td> <td data-bbox="741 1317 1012 1446"> May have a more pronounced decrease in vaccine effectiveness </td> <td data-bbox="1012 1317 1291 1446"> 4 weeks </td> <td data-bbox="1291 1317 1560 1446"> 4 weeks </td> </tr> </tbody> </table>	Medication(s)	Effect on vaccination	Delay of vaccination after treatment*	Delay of treatment after vaccination**	Glatiramer acetate (any type) Interferon-beta (any type) Teriflunomide Dimethyl fumarate (or any type of fumaric acid ester) Natalizumab	Little to no effect	None required	None required	Fingolimod Ozanimod Siponimod	May have a modest decrease in vaccine effectiveness	None required	4 weeks for treatment initiation; no delay for treatment continuation	Ocrelizumab Rituximab	May have a more pronounced decrease in vaccine effectiveness	4 weeks	4 weeks	<ul style="list-style-type: none"> • Studies from around the world show COVID-19 vaccines are safe for people with an autoimmune disease. • The vaccine antibody response in MS patients may not be as strong as the immune response in individuals who do not have MS. This will depend on the disease process and the client's MS treatment. Immunized individuals still need to take precautions against COVID-19 disease. • Based on your therapy the recommendation is as follows: [refer to treatments in Table]. • Do you have any additional questions or concerns about getting immunized with the COVID-19 vaccine? • (If the treatment plan in Table supports immunization) Do you consent to being immunized with the (Brand) of COVID-19 vaccine?
Medication(s)	Effect on vaccination	Delay of vaccination after treatment*	Delay of treatment after vaccination**															
Glatiramer acetate (any type) Interferon-beta (any type) Teriflunomide Dimethyl fumarate (or any type of fumaric acid ester) Natalizumab	Little to no effect	None required	None required															
Fingolimod Ozanimod Siponimod	May have a modest decrease in vaccine effectiveness	None required	4 weeks for treatment initiation; no delay for treatment continuation															
Ocrelizumab Rituximab	May have a more pronounced decrease in vaccine effectiveness	4 weeks	4 weeks															

Condition	Recommendations				Script
	Ofatumumab	May have a more pronounced decrease in vaccine effectiveness	4 weeks	4 weeks	
	Cladribine Alemtuzumab	Unlikely to affect vaccine response after immune reconstitution has taken place		4 weeks	
	<p>*: The time period after a treatment dose during which vaccine should not be administered. **: The time period after a vaccination series (i.e. all doses) during which treatment should not be (re)started.</p> <p><u>NACI Recommendation:</u> NACI preferentially recommends that a complete vaccine series with an mRNA COVID19 vaccine should be offered to individuals in the authorized age group with an autoimmune condition. If an mRNA vaccine is contraindicated, another authorized COVID-19 vaccine should be offered. Informed consent should include discussion about the emerging evidence on the safety of mRNA COVID-19 vaccines in these populations. (Strong NACI Recommendation)</p> <p>NACI July 22, 2021 https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html?hq_e=el&hq_m=2188311&hq_l=1&hq_v=91d220e044).</p>				
<p>Tuberculin (TB) Skin Test or TB Blood Work (IGRA)</p>	<ul style="list-style-type: none"> If TB skin testing or TB blood work is required, it should be administered and read before immunization or delayed for at least 4 weeks after vaccination with COVID-19 vaccine. Vaccination with COVID-19 vaccines may take place at any time after all steps of tuberculin skin testing have been completed. <p>NACI July 22, 2021 https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html?hq_e=el&hq_m=2188311&hq_l=1&hq_v=91d220e044).</p>				<ul style="list-style-type: none"> Have you had a tuberculin (TB) skin test or need TB blood work (IGRA) done? <p>If testing has been done but not read/completed:</p> <ul style="list-style-type: none"> Receiving the COVID-19 vaccine prior to having all steps of the TB test completed may cause the test to show a false-negative result which means the test negative result but it should be a positive result. The recommendation is to wait until your test result is read before receiving the COVID-19 vaccine.

Condition	Recommendations	Script
		<ul style="list-style-type: none"> • (If recommendation in second column supports immunization) Do you have any additional questions or concerns about getting immunized with the COVID-19 vaccine?
Thrombosis and Thrombocytopenia	<p>AstraZeneca/COVISHIELD & Janssen COVID-19 Vaccines Only:</p> <p>CONTRAINDICATIONS:</p> <ul style="list-style-type: none"> • Clients with a history of the following conditions should not receive this vaccine: <ul style="list-style-type: none"> ○ Heparin Induced Thrombocytopenia (HIT) <ul style="list-style-type: none"> ▪ HIT antibody lingering might interfere with lab assay to detect the VIPIT/VITT antibody and may complicate management ○ Thrombotic Antiphospholipid Antibody Syndrome (APS) ○ Major venous or arterial thrombosis with thrombocytopenia following a viral vector COVID-19 vaccine <p>PRECAUTIONS:</p> <ul style="list-style-type: none"> • Cerebral Sinus Venous Thrombosis (CVST) with thrombocytopenia <ul style="list-style-type: none"> ○ Should only receive a viral vector COVID-19 vaccine if the potential benefits outweigh the potential risks. An alternate COVID-19 vaccine should be offered. <p>Data on Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) cases outlined by NACI:</p> <ul style="list-style-type: none"> • Cases of VITT usually occur between 4 and 28 days after receipt of a viral vector COVID-19 vaccine, and patients should be monitored for symptoms up to 42 days. • The rate of VITT is estimated to be between 1 per 26,000 and 1 per 100,000 persons vaccinated with a first dose of AstraZeneca/COVISHIELD COVID-19 vaccine. As of June 1, 2021, PHAC has estimated the rate of VITT in Canada to be 1 in 73,000 doses administered, however, as investigations continue, this rate could be as high as 1 in 50,000. • The frequency of VITT following a second dose of AstraZeneca vaccine is currently reported between 1 per 600,000 and 1 per 750,000 individuals vaccinated with a second dose but continues to evolve, based on vaccine safety surveillance data from the United Kingdom. • The case fatality rate of VITT also varies between countries, and ranges between 20 and 50%. 	<ul style="list-style-type: none"> • Due to very rare reports of a combination of blood clots and low levels of blood platelets following immunization with the AstraZeneca/COVISHIELD vaccine, it is not recommended people with a history of this condition to receive this vaccine.

Condition	Recommendations	Script
Capillary Leak Syndrome	<p>AstraZeneca/COVISHIELD COVID-19 Vaccines Only:</p> <ul style="list-style-type: none"> This vaccine is contraindicated for clients with a history of capillary leak syndrome. <p>NACI July 22, 2021 https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html?hq_e=el&hq_m=2188311&hq_l=1&hq_v=91d220e044).</p>	<ul style="list-style-type: none"> Due to rare reports of capillary leak syndrome after vaccination, people with a history of this CLS should not be vaccinated with the AstraZeneca/COVISHIELD COVID-19 vaccine.
Myocarditis and/or Pericarditis	<p>mRNA COVID-19 Vaccines Only:</p> <p>As a precautionary measure, the second dose in the mRNA COVID-19 vaccination series should be deferred in individuals who developed myocarditis or pericarditis following the first dose of an mRNA COVID-19 vaccine as an adverse event until more information is available. It is unclear if people who developed myocarditis or pericarditis after a first dose of an mRNA COVID-19 vaccine may be at increased risk of further adverse cardiac effects following a second dose of the vaccine. NACI will continue to monitor the evidence and update recommendations as needed.</p> <p>If an individual is at high risk of COVID-19 acquisition or severe outcome due to community transmission or underlying condition, then a decision to get the second dose should be made in consultation with the individual’s physician (cardiologist if possible) with the patient’s informed consent.</p> <p>Decisions about proceeding with the second dose should include a conversation between the patient, their parent/guardian/caregiver (when relevant), and their clinical team. These individuals should be informed of the risks of myocarditis and pericarditis following a second mRNA COVID-19 vaccine dose and advised to seek medical attention if they develop symptoms.</p> <p>People with a history of myocarditis or pericarditis following a first dose of an mRNA COVID19 vaccine, who choose or are recommended by their specialist to receive the second dose of an mRNA COVID-19 vaccine, should wait at least until their episode of myocarditis or pericarditis has completely resolved. This includes resolution of symptoms attributed to myocarditis or pericarditis, as well as no evidence of ongoing heart inflammation or sequelae as determined by the person’s clinical team, which may include a cardiologist, and special testing to assess cardiac recovery.</p> <p>Data on myocarditis and pericarditis as outlined by NACI:</p>	<ul style="list-style-type: none"> Due to very rare reports of myocarditis (inflammation of the heart) and/or pericarditis (inflammation of the outer lining of the heart), people with a history of these conditions discuss immunization with an mRNA vaccine prior to receiving.

Condition	Recommendations	Script
	<p>Based on cases reported internationally, available information indicates that cases of myocarditis and pericarditis after vaccination with an mRNA COVID-19 vaccine occur:</p> <ul style="list-style-type: none"> • More often after the second dose • Usually within a week after vaccination • More often in adolescents and young adults • More often in males than females. <p>NACI July 22, 2021 https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html?hq_e=el&hq_m=2188311&hq_l=1&hq_v=91d220e044).</p>	

References

1. Cohn A, Mbaeyi S. What clinicians need to know about the Pfizer-BioNTech COVID-19 vaccine. Centers for Disease Control and Prevention (CDC). 2020.
2. NACI July 22, 2021 https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html?hq_e=e&hq_m=2188311&hq_l=1&hq_v=91d220e044). American Autoimmune Related Disease Ltd. <https://www.aarda.org/diseaselist/>
3. Centers for Disease Control: <https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>

Common Auto Immune Conditions*¹

*This is not an exhaustive list

Addison’s	Guillain-Barre syndrome	Optic Neuritis
Alopecia areata	Hashimoto’s thyroiditis	Psoriasis
Amyloidosis	Hemolytic anemia	Psoriatic arthritis
Ankylosing spondylitis	Henoch-Schonlein purpura	Raynaud’s syndrome
Celiac disease	Juvenile arthritis	Restless legs syndrome
Crohn’s disease	Kawasaki disease	Rheumatoid arthritis
Diabetes (type 1)	Lupus	Sarcoidosis
Endometriosis	Meniere’s disease	Scleroderma
Erythema nodosum	Multiple Sclerosis	Thrombocytopenic purpura
Fibromyalgia	Myasthenia gravis	Ulcerative Colitis
Graves’ disease	Neutropenia	

¹list obtained American Autoimmune Related Disease Ltd. <https://www.aarda.org/diseaselist/>